Is atypical EGFR-mutated NSCLC becoming Johnson & Johnson’s next precision oncology battleground?
Atypical EGFR lung cancer lacks clear first-line answers. Rybrevant plus Lazcluze may change that, but trial size still matters.
Atypical EGFR lung cancer lacks clear first-line answers. Rybrevant plus Lazcluze may change that, but trial size still matters.